We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

498 hedge funds and large institutions have $22.6B invested in Alnylam Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 96 funds opening new positions, 167 increasing their positions, 160 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more first-time investments, than exits

New positions opened: 96 | Existing positions closed: 44

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

10% more funds holding

Funds holding: 452 → 498 (+46)

8% more capital invested

Capital invested by funds: $20.9B → $22.6B (+$1.71B)

4% more repeat investments, than reductions

Existing positions increased: 167 | Existing positions reduced: 160

0.29% less ownership

Funds ownership: 94.23% → 93.94% (-0.29%)

17% less call options, than puts

Call options by funds: $267M | Put options by funds: $321M

Holders
498
Holders Change
+46
Holders Change %
+10.18%
% of All Funds
7.26%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
96
Increased
167
Reduced
160
Closed
44
Calls
$267M
Puts
$321M
Net Calls
-$54.7M
Net Calls Change
-$24.4M

Top Buyers

1
Norges Bank
Norges Bank
Norway
+$144M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$133M
3
Capital International Investors
Capital International Investors
California
+$83.3M
4
Morgan Stanley
Morgan Stanley
New York
+$68.8M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$48.9M

Top Sellers

1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$204M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$165M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$98.1M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$75.1M
5
Capital World Investors
Capital World Investors
California
-$60.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
LJAC
326
L.J. Altfest & Co
New York
$397K +$80.9K +475 +30%
MFAM
327
Motley Fool Asset Management
Virginia
$390K -$33.4K -196 -9%
BFG
328
Bleakley Financial Group
New Jersey
$388K +$68.8K +404 +25%
FCM
329
Farallon Capital Management
California
$383K – – –
SNBOSD
330
Security National Bank of So Dak
Iowa
$383K – – –
SS
331
Simplicity Solutions
Minnesota
$382K +$63.9K +375 +23%
OSAM
332
O'Shaughnessy Asset Management
Connecticut
$381K +$67.5K +396 +25%
O
333
Ossiam
France
$380K – – –
GS
334
GTS Securities
New York
$376K +$335K +1,966 New
SSA
335
Schonfeld Strategic Advisors
New York
$374K -$6.84M -40,154 -95%
BA
336
Bridgewater Associates
Connecticut
$373K +$11.1K +65 +3%
AIG
337
American International Group
New York
$360K -$8.69K -51 -3%
Janney Montgomery Scott
338
Janney Montgomery Scott
Pennsylvania
$360K +$321K +1,883 New
VA
339
Vident Advisory
Georgia
$358K +$21.1K +124 +7%
YIH
340
Y-Intercept (HK)
Hong Kong
$355K +$316K +1,855 New
JGGDR
341
JGP Global Gestao de Recursos
Brazil
$354K -$1.02K -6 -0.3%
VIM
342
VELA Investment Management
Ohio
$348K -$272K -1,599 -47%
VEA
343
Virtus ETF Advisers
New York
$335K +$36.8K +216 +14%
BPCE
344
Bank Pictet & Cie (Europe)
Germany
$331K -$10.7K -63 -4%
LWCFA
345
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$329K – – –
PCIA
346
Prime Capital Investment Advisors
Kansas
$328K +$292K +1,716 New
FC
347
FORA Capital
Florida
$326K +$290K +1,705 New
PCM
348
Prelude Capital Management
New York
$317K +$282K +1,656 New
BPA
349
Beacon Pointe Advisors
California
$313K -$9.37K -55 -3%
SP
350
Systematic Portfolios
New York
$313K +$279K +1,636 New
12 13
14
15 16

ALNY Hedge Fund Activity: Q4 2023 in Review

498 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2023, worth a combined $22.6B — up 8.2% from $20.9B a quarter earlier.

Buyers outnumbered sellers: 96 funds opened new ALNY positions and 44 closed out — a net gain of 52 holders — while 167 added to existing stakes and 160 trimmed.

The largest buyer was Norges Bank, adding an estimated $144M. The largest seller was Baillie Gifford & Co, cutting an estimated $204M.

  • 498 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2023, up from 452 in Q3 2023.
  • Funds reported $22.6B of Alnylam Pharmaceuticals stock for Q4 2023, up 8.2% quarter-over-quarter.
  • 96 funds opened new Alnylam Pharmaceuticals positions in Q4 2023 and 44 closed out, a net change of +52 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q4 2023 was Norges Bank, an estimated $144M added.
  • The largest Alnylam Pharmaceuticals seller in Q4 2023 was Baillie Gifford & Co, an estimated $204M sold.

Based on aggregated 13F filings for Q4 2023.